This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06064500
Expanded Access Status : Available
First Posted : October 3, 2023
Last Update Posted : November 13, 2023
Information provided by (Responsible Party):

Brief Summary:
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen).

Condition or disease Intervention/treatment
Small Cell Lung Cancer Drug: Tarlatamab

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: A Phase 3b, Multicenter, Single-arm, Expanded Access Protocol of Tarlatamab (AMG 757) for the Treatment of Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Intervention Details:
  • Drug: Tarlatamab
    Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
    Other Name: AMG 757

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically or cytologically confirmed SCLC
  • Extensive-stage, unable to be encompassed in a tolerable radiation plan
  • Progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy
  • Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1
  • Minimum life expectancy of 12 weeks

Exclusion Criteria:

  • Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology
  • Untreated or symptomatic central nervous system (CNS) metastases
  • Active hepatitis B or hepatitis C virus infection
  • Eligible for participation in any Amgen-sponsored ongoing clinical study of the investigational product
  • Currently or previously enrolled in a prior tarlatamab study
  • Female participants and/or male participants with female partners who are pregnant, breastfeeding, planning to become pregnant or donate eggs while on study through 72 days after the last dose of tarlatamab
  • Male and female participants unwilling to practice abstinence and/or use protocol specified method of contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT06064500

Layout table for location contacts
Contact: Amgen Call Center 866-572-6436

Sponsors and Collaborators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen Identifier: NCT06064500    
Other Study ID Numbers: 20220100
First Posted: October 3, 2023    Key Record Dates
Last Update Posted: November 13, 2023
Last Verified: November 2023
Keywords provided by Amgen:
Lung cancer
Extensive-stage small cell lung cancer
AMG 757
Bispecific T-Cell Engager
Delta-like ligand 3
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
AMG 757
Antineoplastic Agents